Latest & greatest articles for Phosphodiesterase Inhibitor

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on Phosphodiesterase Inhibitor or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on Phosphodiesterase Inhibitor and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for Phosphodiesterase Inhibitor

1. The hemodynamic interactions of the combined treatment with α-blockers and phosphodiesterase-5 inhibitors compared with α-blocker monotherapy: A systematic review and meta-analysis Full Text available with Trip Pro

The hemodynamic interactions of the combined treatment with α-blockers and phosphodiesterase-5 inhibitors compared with α-blocker monotherapy: A systematic review and meta-analysis Redirecting

2020 European Urology Open Science

2. Phosphodiesterase-4 inhibitors for chronic obstructive pulmonary disease. (Abstract)

Phosphodiesterase-4 inhibitors for chronic obstructive pulmonary disease. Chronic obstructive pulmonary disease (COPD) is associated with cough, sputum production or dyspnoea, and a reduction in lung function, quality of life, and life expectancy. Apart from smoking cessation, no other treatments that slow lung function decline are available. Roflumilast and cilomilast are oral phosphodiesterase-4 (PDE₄) inhibitors proposed to reduce the airway inflammation and bronchoconstriction seen in COPD (...) . This Cochrane Review was first published in 2011, and was updated in 2017 and 2020.To evaluate the efficacy and safety of oral PDE₄ inhibitors for management of stable COPD.We identified randomised controlled trials (RCTs) from the Cochrane Airways Trials Register (date of last search 9 March 2020). We found other trials at web-based clinical trials registers.We included RCTs if they compared oral PDE₄ inhibitors with placebo in people with COPD. We allowed co-administration of standard COPD therapy.We used

2020 Cochrane

3. Taking a hard look at the evidence: Phosphodiesterase-5-inhibitors in erectile dysfunction

Taking a hard look at the evidence: Phosphodiesterase-5-inhibitors in erectile dysfunction Tools for Practice is proudly sponsored by the Alberta College of Family Physicians (ACFP). ACFP is a provincial, professional voluntary organization, representing more than 4,800 family physicians, family medicine residents, and medical students in Alberta. Established over sixty years ago, the ACFP strives for excellence in family practice through advocacy, continuing medical education and primary care (...) research. www.acfp.ca October 15, 2019 (en français) Don’t miss your last chance to pipe into the PEIP conference! Registration closes Friday, October 18 th . Click here to register. Taking a hard look at the evidence: Phosphodiesterase-5- inhibitors in erectile dysfunction Clinical Question: What is the efficacy and safety of phosphodiesterase-5-inhibitors (PDE5 inhibitors) for erectile dysfunction? Bottom Line: PDE5 inhibitors increase the proportion of successful sexual intercourse attempts to ~65

2019 Tools for Practice

4. Effect of cilostazol, a phosphodiesterase-3 inhibitor, on coronary artery stenosis and plaque characteristics in patients with type 2 diabetes: ESCAPE study (Abstract)

Effect of cilostazol, a phosphodiesterase-3 inhibitor, on coronary artery stenosis and plaque characteristics in patients with type 2 diabetes: ESCAPE study To perform a prospective study to evaluate the effect of cilostazol (CTZ) compared with aspirin (acetylsalicylic acid; ASA) in Korean people with diabetes and subclinical coronary atherosclerosis.A total of 100 people with diabetes who had mild to moderate coronary atherosclerosis, assessed by coronary computed tomographic angiography (CCTA

2019 EvidenceUpdates

5. Erectile dysfunction: Phosphodiesterase-5 (PDE-5) inhibitors

Erectile dysfunction: Phosphodiesterase-5 (PDE-5) inhibitors Phosphodiesterase-5 (PDE-5) inhibitors | Prescribing information | Erectile dysfunction | CKS | NICE Search CKS… Menu Phosphodiesterase-5 (PDE-5) inhibitors Erectile dysfunction: Phosphodiesterase-5 (PDE-5) inhibitors Last revised in August 2019 Phosphodiesterase-5 (PDE-5) inhibitors What are the contraindications and cautions? Contraindications Do not prescribe a phosphodiesterase-5 (PDE-5)inhibitor to men: Receiving certain drugs (...) interval. Prescribe sildenafil and avanafil with caution to men with active peptic ulceration or bleeding disorders. [ ; ; ; ; ] Adverse effects Common or very common adverse effects of phosphodiesterase-5 (PDE-5) inhibitors include back pain, dyspepsia, flushing, migraine, myalgia, nasal congestion, dizziness, nausea, and vomiting. Uncommon but serious adverse effects of PDE-5 inhibitors include: Visual disturbances, including non-arteritic anterior ischaemic optic neuropathy (NAION). Stop the PDE-5

2018 NICE Clinical Knowledge Summaries

7. Phosphodiesterase Type 5 Inhibitors for Penile Rehabilitation Post Radical Prostatectomy: A Review of Clinical Effectiveness and Guidelines

Phosphodiesterase Type 5 Inhibitors for Penile Rehabilitation Post Radical Prostatectomy: A Review of Clinical Effectiveness and Guidelines Phosphodiesterase Type 5 Inhibitors for Penile Rehabilitation Post Radical Prostatectomy: A Review of Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Phosphodiesterase Type 5 Inhibitors for Penile Rehabilitation Post Radical Prostatectomy: A Review of Clinical Effectiveness and Guidelines Phosphodiesterase Type 5 Inhibitors (...) for Penile Rehabilitation Post Radical Prostatectomy: A Review of Clinical Effectiveness and Guidelines Published on: August 24, 2017 Project Number: RC0915-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness of phosphodiesterase type 5 inhibitors (PDE-5Is) for the treatment of adults requiring penile rehabilitation post radical prostatectomy? What are the evidence-based guidelines associated with penile

2017 Canadian Agency for Drugs and Technologies in Health - Rapid Review

8. In Chronic Cardiac Decompensation with Reduced Left Ventricular Ejection Fraction, Phosphodiesterase-5 Inhibition Exerts Significant Effects on some Clinical, Functional and Hemodynamic Outcomes: a Meta-Analysis Full Text available with Trip Pro

, Phosphodiesterase-5 Inhibition Exerts Significant Effects on some Clinical, Functional and Hemodynamic Outcomes: a Meta-Analysis. Preprints 2017, 2017030177 (doi: 10.20944/preprints201703.0177.v1). Copy CANCEL COPY CITATION DETAILS Abstract Background: In patients with pulmonary arterial hypertension, substantial clinical benefits have been reported with the use of phosphodiesterase-5 inhibitors(PDE5i) . Moreover, some studies would have proven useful effects of PDE5i also on the clinical picture (...) In Chronic Cardiac Decompensation with Reduced Left Ventricular Ejection Fraction, Phosphodiesterase-5 Inhibition Exerts Significant Effects on some Clinical, Functional and Hemodynamic Outcomes: a Meta-Analysis In Chronic Cardiac Decompensation with Reduced Left Ventricular Ejection Fraction, Phosphodiesterase-5 Inhibition Exerts Significant Effects on some Clinical, Functional and Hemodynamic Outcomes: a Meta-Analysis[v1] | Preprints Share this article with Create alert Email: Submit

2017 MDPI AG

9. Effects of Phosphodiesterase Type 5 (PDE-5) Inhibitors in the Management of Pulmonary Arterial Hypertension: A Systematic Review and Meta-analysis Pointing on Peak VO2 Full Text available with Trip Pro

. (2013) Effects of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: A randomized clinical trial. JAMA 309: 1268-1277. 14. Wu X, Y ang T, Zhou Q, Li S, Huang L, et al. (2013) Additional use of a phosphodiesterase 5 inhibitor in patients with pulmonary hypertension secondary to chronic systolic heart failure: a meta-analysis. Eur J Heart Fail 16: 444-453. 15. Garg N, Sharma MK, Sinha N (2006) Role of oral sildenafil in severe (...) Effects of Phosphodiesterase Type 5 (PDE-5) Inhibitors in the Management of Pulmonary Arterial Hypertension: A Systematic Review and Meta-analysis Pointing on Peak VO2 Effects of Phosphodiesterase Type 5 (PDE-5) Inhibitors in the Management of Pulmonary Arterial Hypertension: A Systematic Review and Meta-analysis Pointing on Peak VO 2 Rutahoile WM 1 , David NM 1 , Angela AP 1 , Abdallah ZH 1 , Xiao Li Zhou 2 , Huang Wei 1 and Lei Han 1* 1 The First Affiliated Hospital of Chongqing Medical

2017 Journal of Hypertension: Open Access

10. Phosphodiesterase Type 5 Inhibitors and the Risk of Melanoma Skin Cancer (Abstract)

Phosphodiesterase Type 5 Inhibitors and the Risk of Melanoma Skin Cancer The association between phosphodiesterase type 5 inhibitors (PDE5-Is), drugs used in the treatment of erectile dysfunction (ED), and melanoma skin cancer is controversial.To assess whether the use of PDE5-Is is associated with an increased risk of melanoma skin cancer.Using the UK Clinical Practice Research Datalink, we assembled a cohort of men newly diagnosed with ED between 1998 and 2014 and followed until 2015. PDE5-I (...) with basal and squamous cell carcinoma, with an unclear association with numbers of prescriptions and pills received.The use of PDE5-Is was not associated with an overall increased risk of melanoma skin cancer. The increased risks observed in the highest prescription and pill categories require further validation.In this study, the use of phosphodiesterase type 5 inhibitors was not associated with an increased risk of melanoma skin cancer.Copyright © 2016. Published by Elsevier B.V.

2016 EvidenceUpdates

11. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3) Full Text available with Trip Pro

Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3) To evaluate apremilast treatment in patients with active psoriatic arthritis, including current skin involvement, despite prior therapy with conventional disease-modifying antirheumatic drugs and/or biologic agents.Patients (N=505) were randomised (1:1:1) to placebo, apremilast 20 mg twice daily, or apremilast 30 mg twice

2016 EvidenceUpdates Controlled trial quality: uncertain

12. Phosphodiesterase Type 5 Inhibitor Use and Disease Recurrence After Prostate Cancer Treatment Full Text available with Trip Pro

Phosphodiesterase Type 5 Inhibitor Use and Disease Recurrence After Prostate Cancer Treatment Phosphodiesterase type 5 inhibitor (PDE5i) use is common for management of erectile dysfunction. Single-institution studies have reported conflicting data on the relationship between PDE5i use and biochemical recurrence of prostate cancer (BCR) after radical prostatectomy.To evaluate the association between PDE5i use and BCR after radical prostatectomy and radiation therapy in a nationwide population

2015 EvidenceUpdates

13. Apremilast: A Phosphodiesterase 4 Inhibitor for the Treatment of Psoriatic Arthritis. Full Text available with Trip Pro

Apremilast: A Phosphodiesterase 4 Inhibitor for the Treatment of Psoriatic Arthritis. Psoriatic arthritis (PsA) is a spondyloarthritis that occurs in up to 30% of psoriasis patients. Patients with PsA are at risk for decreased quality of life due to both joint and skin symptoms, impaired physical function and disease progression. Treatments include non-steroidal anti-inflammatory drugs, conventional systemic disease-modifying anti-rheumatic drugs (DMARDs) such as methotrexate, and biologic (...) agents, including tumor necrosis factor-α inhibitors. The most recently introduced treatment option is apremilast, an oral phosphodiesterase 4 inhibitor.This review provides an in-depth discussion of apremilast's mechanism of action, and evidence of its clinical efficacy and safety from the Psoriatic Arthritis Long-term Assessment of Clinical Efficacy (PALACE) phase III pivotal clinical trials (PALACE 1, 2, and 3).These trials demonstrate that apremilast is effective for the treatment of active PsA

2014 Rheumatology and therapy Controlled trial quality: uncertain

14. Effect of Phosphodiesterase-5 Inhibition on Exercise Capacity and Clinical Status in Heart Failure With Preserved Ejection Fraction: A Randomized Clinical Trial. Full Text available with Trip Pro

Effect of Phosphodiesterase-5 Inhibition on Exercise Capacity and Clinical Status in Heart Failure With Preserved Ejection Fraction: A Randomized Clinical Trial. Studies in experimental and human heart failure suggest that phosphodiesterase-5 inhibitors may enhance cardiovascular function and thus exercise capacity in heart failure with preserved ejection fraction (HFPEF).To determine the effect of the phosphodiesterase-5 inhibitor sildenafil compared with placebo on exercise capacity (...) (94.2) (P = .85). Changes in 6-minute walk distance at 24 weeks in patients who received placebo (15.0 m [IQR, -26.0 to 45.0]) or sildenafil (5.0 m [IQR, -37.0 to 55.0]; P = .92) were also not significantly different. Adverse events occurred in 78 placebo patients (76%) and 90 sildenafil patients (80%). Serious adverse events occurred in 16 placebo patients (16%) and 25 sildenafil patients (22%).Among patients with HFPEF, phosphodiesterase-5 inhibition with administration of sildenafil for 24 weeks

2013 JAMA Controlled trial quality: predicted high

15. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial (Abstract)

Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial Infused and inhaled treprostinil are effective for treatment of pulmonary arterial hypertension (PAH), although their administration routes have limitations. This study assessed the efficacy and safety of bid oral sustained-release treprostinil in the treatment of PAH (...) with a concomitant endothelin receptor antagonist (ERA) and/or phosphodiesterase type 5 inhibitor.A 16-week, multicenter, double-blind, placebo-controlled study was conducted in 350 patients with PAH randomized to placebo or oral treprostinil. All patients were stable on background ERA, PDE-5 inhibitor, or both. Primary end point was Hodges-Lehmann placebo-corrected median difference in change from baseline 6-min walk distance (6MWD) at week 16. Secondary end points included time to clinical worsening, change

2012 EvidenceUpdates Controlled trial quality: predicted high

16. Phosphodiesterase 5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review

Phosphodiesterase 5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2011 DARE.

17. Phosphodiesterase-5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review and meta-analysis

Phosphodiesterase-5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review and meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2011 DARE.

18. Pulmonary Hypertension in Heart Failure With Preserved Ejection Fraction: A Target of Phosphodiesterase-5 Inhibition in a 1-Year Study Full Text available with Trip Pro

Pulmonary Hypertension in Heart Failure With Preserved Ejection Fraction: A Target of Phosphodiesterase-5 Inhibition in a 1-Year Study The prevalence of heart failure with preserved ejection fraction is increasing. The prognosis worsens with pulmonary hypertension and right ventricular (RV) failure development. We targeted pulmonary hypertension and RV burden with the phosphodiesterase-5 inhibitor sildenafil.Forty-four patients with heart failure with preserved ejection fraction (heart failure (...) similar at 12 months.The multifaceted response to phosphodiesterase-5 inhibition in heart failure with preserved ejection fraction includes improvement in pulmonary pressure and vasomotility, RV function and dimension, left ventricular relaxation and distensibility (structural changes and/or ventricular interdependence), and lung interstitial water metabolism (wedge pulmonary pressure decrease improving hydrostatic balance and right atrial pressure reduction facilitating lung lymphatic drainage

2011 EvidenceUpdates Controlled trial quality: uncertain

19. Phosphodiesterase 5 inhibitors: a review of the clinical effectiveness and cost-effectiveness

Phosphodiesterase 5 inhibitors: a review of the clinical effectiveness and cost-effectiveness Phosphodiesterase 5 inhibitors: a review of the clinical effectiveness and cost-effectiveness Phosphodiesterase 5 inhibitors: a review of the clinical effectiveness and cost-effectiveness Canadian Agency for Drugs and Technologies in Health Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment (...) has been made for the HTA database. Citation Canadian Agency for Drugs and Technologies in Health. Phosphodiesterase 5 inhibitors: a review of the clinical effectiveness and cost-effectiveness. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). 2010 Authors' conclusions The majority of the information identified addressed the question about comparative clinical effectiveness of the PDE=5 inhibitors for the treatment of erectile dysfunction. Two meta-analyses demonstrated

2010 Health Technology Assessment (HTA) Database.

20. Oral Phosphodiesterase-5 Inhibitors and Hormonal Treatments for Erectile Dysfunction: A Systematic Review and Meta-analysis. (Abstract)

Oral Phosphodiesterase-5 Inhibitors and Hormonal Treatments for Erectile Dysfunction: A Systematic Review and Meta-analysis.

2009 Annals of Internal Medicine